Gilead Sciences, Inc. $GILD Shares Bought by Wrapmanager Inc.

Wrapmanager Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 32.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,300 shares of the biopharmaceutical company’s stock after buying an additional 2,254 shares during the period. Wrapmanager Inc.’s holdings in Gilead Sciences were worth $1,031,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Brighton Jones LLC increased its holdings in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $215,000. Edgestream Partners L.P. lifted its holdings in shares of Gilead Sciences by 99.0% during the first quarter. Edgestream Partners L.P. now owns 18,401 shares of the biopharmaceutical company’s stock worth $2,062,000 after purchasing an additional 9,152 shares during the period. Massachusetts Financial Services Co. MA grew its position in Gilead Sciences by 24.2% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 94,286 shares of the biopharmaceutical company’s stock valued at $10,565,000 after buying an additional 18,368 shares during the last quarter. Finally, Parcion Private Wealth LLC acquired a new position in Gilead Sciences in the 1st quarter valued at $218,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the sale, the executive vice president directly owned 43,676 shares in the company, valued at $5,365,596.60. The trade was a 55.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 94,646 shares of company stock worth $11,311,286 over the last ninety days. 0.27% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on GILD. Sanford C. Bernstein restated an “outperform” rating on shares of Gilead Sciences in a research report on Monday, November 3rd. TD Cowen boosted their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Wolfe Research raised their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. UBS Group lifted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Finally, BMO Capital Markets boosted their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $129.13.

Gilead Sciences Trading Up 1.5%

Shares of GILD opened at $125.20 on Friday. Gilead Sciences, Inc. has a twelve month low of $86.08 and a twelve month high of $127.68. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $155.33 billion, a P/E ratio of 24.94, a PEG ratio of 0.81 and a beta of 0.32. The firm’s 50-day moving average is $117.24 and its two-hundred day moving average is $112.64.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.